Clinical Trials
14 trialsNCT05065866 2025-12-04
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03792256 2025-03-21
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase 1 Completed
NCT03833180 2024-01-12
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Completed
NCT02916979 2023-10-18
FluBuATG
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT01991184 2022-06-21
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Phase 1 Completed
NCT02046291 2021-06-08
Safety of Romiplostim (Nplate®) Following UCBT
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01643603 2020-12-17
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01680991 2016-04-25
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Phase 1 Completed
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT00464113 2015-08-21
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
Exelixis
Phase 1 Terminated
NCT01292135 2014-07-24
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
Phase 1 Completed
NCT00849654 2013-05-22
PCYC-04753
Pharmacyclics LLC.
Phase 1 Completed
NCT00108108 2012-10-01
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
Novartis
Phase 1 Terminated
NCT00313079 2012-07-03
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Completed